RYTM / Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. is focused on developing treatments for orphan obesity syndromes caused by defects in the MC4R pathway. Their product Imc more_horizontal

BOSTON, July 18, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transf more_horizontal

Today, we check back in on Rhythm Pharmaceuticals, Inc., an entrant into the fast-growing weight management medicine space. The company is simultaneou more_horizontal

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q1 2023 Earnings Conference Call May 2, 2023 8:00 AM ET Company Participants David Connolly - Executive Di more_horizontal

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 8.54% and 24.56%, respectively, for the quarter ended December 2022. D more_horizontal

Rhythm Pharmaceuticals is planning to get approvals for setmelanotide in an incremental fashion. Each new approval in a rare disease will add to the t more_horizontal

Here's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals. more_horizontal

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2022 Results Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants David Connolly - I more_horizontal